Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC)

被引：0
|
作者：
Jansen, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Vernaz-Gris, M. [1 ,2 ,3 ,4 ,5 ,6 ]
DesJardins, C. [1 ,2 ,3 ,4 ,5 ,6 ]
Wong, N. [1 ,2 ,3 ,4 ,5 ,6 ]
Campone, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Cortes, J. [1 ,2 ,3 ,4 ,5 ,6 ]
Wanders, J. [1 ,2 ,3 ,4 ,5 ,6 ]
Shuster, D. [1 ,2 ,3 ,4 ,5 ,6 ]
Fuseau, E. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Eisai Ltd, London, England
[2] EMF Consulting, Aix En Provence, France
[3] Eisai Res Inst, Andover, MA USA
[4] Ctr Rene Gauducheau, St Herblain, France
[5] Vall Hebron Univ Hosp, Barcelona, Spain
[6] Eisai Med Res, Ridgfield Pk, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2524
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Population pharmacokinetics (PPK) of eribulin in cancer patients
    Majid, O.
    Gupta, A.
    Olivo, M.
    Reyderman, L.
    Hussein, Z.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S178 - S178
  • [2] Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer
    Cortes, Javier
    Lorca, Rebeca
    FUTURE ONCOLOGY, 2011, 7 (03) : 355 - 364
  • [3] Eribulin mesylate in patients with locally advanced unresectable or metastatic breast cancer: results and implications of the clinical trials
    Ramnaraign, Brian
    Page, David
    Fornier, Monica
    BREAST CANCER MANAGEMENT, 2015, 4 (03) : 135 - 144
  • [4] Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
    Chen, Lan
    Yan, Xi
    Luo, Ting
    Tian, Tinglun
    He, Ping
    Zhong, Xiaorong
    CANCER MEDICINE, 2024, 13 (10):
  • [5] Effects of dose modification of eribulin mesylate in patients with locally recurrent or metastatic breast cancer
    Faria, Claudio
    Li, Xuan
    Powers, Annette
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [6] ANALYSIS OF ERIBULIN MESYLATE DOSING MODIFICATIONS IMPACT ON ADMINISTRATION PERSISTENCE IN PATIENTS WITH METASTATIC BREAST CANCER (MBC)
    Feinberg, B. A.
    Drenning, J.
    Garofalo, D. F.
    Lal, L.
    Montgomery, J.
    VALUE IN HEALTH, 2015, 18 (07) : A434 - A434
  • [7] Eribulin in Recurrent/Metastatic Breast Cancer (MBC)
    Taha Sethjiwala
    Manikandan Dhanushkodi
    Venkatraman Radhakrishnan
    Jayachandran Perumal Kalaiarasi
    Nikita Mehra
    Archit Joshi
    Arun Kumar Rajan
    Gangothri Selvarajan
    Balasubramanian Ananthi
    Priya Iyer
    Geetha Senguttuvan
    Bharathi Srilatha
    Arvind Krishnamurthy
    Sridevi Velusamy
    Selvaluxmy Ganesarajah
    Trivadi S. Ganesan
    Tenali Gnana Sagar
    Indian Journal of Gynecologic Oncology, 2019, 17
  • [8] POPULATION PHARMACOKINETICS (POPPK) OF SACITUZUMAB GOVITECAN (SG) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC) OR OTHER SOLID TUMORS
    Sathe, A.
    Singh, I.
    Jones, A.
    Diderichsen, P.
    Wang, X.
    Chang, P.
    Phan, S.
    Girish, S.
    Othman, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S70 - S70
  • [9] Eribulin in Recurrent/Metastatic Breast Cancer (MBC)
    Sethjiwala, Taha
    Dhanushkodi, Manikandan
    Radhakrishnan, Venkatraman
    Kalaiarasi, Jayachandran Perumal
    Mehra, Nikita
    Joshi, Archit
    Rajan, Arun Kumar
    Selvarajan, Gangothri
    Ananthi, Balasubramanian
    Iyer, Priya
    Senguttuvan, Geetha
    Srilatha, Bharathi
    Krishnamurthy, Arvind
    Velusamy, Sridevi
    Ganesarajah, Selvaluxmy
    Ganesan, Trivadi S.
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 17 (03)
  • [10] Eribulin mesylate in the treatment of metastatic breast cancer
    Jain, Sarika
    Cigler, Tessa
    BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 21 - 29
12345